Categories:
When is a “Turnaround” not really a “Turnaround”?
Industry Perspectives: A Monthly Research Analyst Series
By Austin Hawley, CFA
“In our view, Willis is a very good company; one which can weather the short-term headwinds it faces and significantly improve its results over the next few years.”
Minimizing Bond Risks through Diligent Credit Analysis
Industry Perspectives: A Monthly Research Analyst Series
By John McClain, CFA
“We like to invest in the bonds of companies that have hard assets with strong market values.”
Unlocking Alere’s Potential
Industry Perspectives: A Monthly Research Analyst Series
By Igor Golalic, CFA
“Alere's core business exhibits characteristics that we want to see in companies in which we invest.”
Executive Summary Using history as a guide, we considered the appropriate price-to-earnings (P/E) ratio that will provide investors a sufficient return on investment, relative to current interest rates, and reward them for equity market risks. We examined periods of extreme...
“With too much capital chasing too few opportunities, the reinsurance industry is facing an existential threat that seems more permanent than cyclical.”
Hospitals: No Longer in the ICU
Industry Perspectives: A Monthly Research Analyst Series
By Kyle Schneider, CFA
“We believe LifePoint's strong free cash flow, flexible balance sheet, and conservative culture create adequate downside protection.”
Mind the Gap
Industry Perspectives: A Monthly Research Analyst Series
“On the surface, Gap quantitatively appears appealing but, in our opinion, less so on a qualitative basis.”
United Technologies: Uniquely Positioned to Capitalize on the Future
Industry Perspectives: A Monthly Research Analyst Series
“UTX management also has a solid historical track record of converting revenues into profits and free cash flow.”
Everyday Brands in the Right Hands
Industry Perspectives: A Monthly Research Analyst Series
By Aaron Monroe, CFA
“The combination of an ownership mentality, long-term perspective, and disciplined capital allocation  – along with Jarden’s portfolio of strong brands – should continue to reward investors.”
Building Shareholder Value through M&A: Valeant Pharmaceuticals
Industry Perspectives: A Monthly Research Analyst Series
By Brian Fontanella, CFA
“Valeant is run by executives who put shareholders first and view capital allocation as their top priority.”
1 2 3 4 5 6 7 8 9 10 11 12
back to top